about
Clinical molecular imaging with radiotracers: current statusNon-invasive molecular imaging of prostate cancer lymph node metastasis.Preclinical evaluation of (111)In-DTPA-INCA-X anti-Ku70/Ku80 monoclonal antibody in prostate cancerGCPII imaging and cancer.Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6.Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancerMolecular imaging of prostate cancer: PET radiotracers.Molecular imaging of prostate cancer: a concise synopsisHumanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumorsMolecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET.PET imaging in prostate cancer: focus on prostate-specific membrane antigenSPECT/CT and tumour imaging.Antibody therapeutics for treating prostate cancer: where are we now and what comes next?Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine.An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors.Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA).Role of Imaging in Prostate Cancer.Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer.Progress in SPECT/CT imaging of prostate cancer.
P2860
Q26994741-BBC1664A-8CA4-4538-9C5F-2C0ABB443DFDQ33557567-D0B55D34-DC1E-43F6-8A60-CC291B3FA699Q33818963-8D2731E2-8DBE-4F6B-A6AE-50A6BE80E012Q33827632-E09937E3-5609-4564-93F7-7A7CE7008E53Q35675446-A4CC3906-9003-4479-BC1F-55A36334600EQ35755818-6F4E9381-EF8E-4CC6-A0EC-014493F20687Q36033412-F71B3944-95BD-44FD-820E-2CF6E88F69E9Q36129937-D4F2AA3B-B57F-40DB-AD37-160A7442D8CAQ37207397-09F1A4B3-EB4F-41EF-B76A-C7A28A3FD9F0Q37289040-C568535D-14D3-4E41-8074-550341AE004FQ37325974-3245B18B-C9BE-4AF3-B2CF-91ED953E32DEQ38099369-5D494869-DCBF-41E5-A1F8-803300E383AEQ38132684-9E931027-AE64-4CF7-8F72-ECD0A330872FQ39000185-095CCCC6-5135-4336-A74A-614AACC7576CQ39389369-A4292381-7D77-438F-BCBE-DC069F6EA77FQ39720680-2E4F8F54-02F0-4C66-9712-1519B84FB531Q39959750-E768D5CD-CEEE-41F0-8788-EDE14D0D7AC5Q42559636-1CF2EB99-455F-4BFA-9984-C6F1A1487F4BQ43193122-B5F2A53E-8E69-4847-AC28-49BC7241C46FQ46044144-5C55C0BB-2432-4BDA-A64D-461CBFBB46CD
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Capromab Pendetide imaging of prostate cancer.
@ast
Capromab Pendetide imaging of prostate cancer.
@en
type
label
Capromab Pendetide imaging of prostate cancer.
@ast
Capromab Pendetide imaging of prostate cancer.
@en
prefLabel
Capromab Pendetide imaging of prostate cancer.
@ast
Capromab Pendetide imaging of prostate cancer.
@en
P2093
P356
P1476
Capromab Pendetide imaging of prostate cancer.
@en
P2093
Haseman MK
Polascik TJ
Rosenthal SA
P304
P356
10.1089/CBR.2000.15.131
P577
2000-04-01T00:00:00Z